Kornimate/medical-research-clean huggingface dataset:
ursodeoxycholic acid prevents total parenteral nutrition cholestasis

Conditions: Cholestasis of Parenteral Nutrition

Summary: this study aims to confirm whether the preventive use of ursodeoxycholic acid on the 5th day after birth in preterm infants who started parenteral nutrition therapy can reduce the occurrence of enteral nutrition-related cholestasis in preterm infants. this study examined the safety and efficacy of ursodeoxycholic acid (udca) in preventing cholestasis associated with total parenteral nutrition in preterm infants.

investigators compared oral administration of udca prophylaxis with no prophylaxis in a randomized, open-label, proof-of-concept trial in preterm neonates with pn therapy.

Eligibility criteria:
inclusion criteria: 1. admission to the hospital within 24 hours after birth 2. gestational ages:28-32 weeks 3. requiring tpn during the first days of life exclusion criteria: 1. major congenital abnormalities, chromosomal abnormality congenital intrauterine infection, genetic metabolic diseases structural liver abnormality 2. surgical treatment was taken during hospitalization 3. with severe symptoms of digestive system disease before tpn 4. incompletion or withdrawal of treatment during hospitalization
pin site infection prevention for open tibial fracture

Conditions: Tibial Fracture

Summary: this study aimed to compare the efficacy of pin-tract infection prevention between silversulfadiazine and dry dressing. methods: 30 patients with an open tibial fracture admitted to songklanagarind hospital from september 2007 to june 2008 and treated by emergency debridement and external fixation were randomized into two groups, one treated with silversulfadiazine for infection prophylaxis (15) and a control group treated with dry dressing only (15). all patients were followed until the external fixator was removed. pin-site infections were assessed and graded at each follow-up visit by an orthopaedist blinded to the mode of treatment. a culture from the pin site was done if an infection occurred.


Eligibility criteria:
inclusion criteria: * open tibial fracture treated with external fixator age between 15-60 years exclusion criteria: * immunocompromised patients (diabetes, hiv or malignancy)

Keywords: pin-site infection silversulfadiazine open fracture open tibial fracture underwent external fixator
direct anterior versus posterior total hip arthroplasty surgical approaches

Conditions: Osteoarthritis; Avascular Necrosis

Summary: hip replacement is a common surgical procedure performed to relieve the pain and disability. in general, the surgery consists of replacing the diseased or damaged joint surfaces of the hip with metal and plastic components shaped to allow continued motion of the hip. surgeons may perform this operation in several different ways. the purpose of this study is to compare two different methods of performing total hip replacement. the investigators hypothesize that subjects treated with the anterior approached may show improved function during the early postoperative period, but that no differences in pain or function will be present after the first postoperative year. in this study, patients that have elected to have hip replacement and consented to participate in the study will be randomized to have his or her hip replaced using one of two surgical techniques. subjects will be randomized to be implanted using either an anterior or posterior approach. with the anterior approach, the study surgeon will use an incision that is on the front of the hip, and with the posterior approach, the incision will be more on the backside of your hip. the study surgeon has done more than 300 total hip replacements with both of these techniques. a baseline assessment will be conducted before hip replacement surgery that includes x-rays, functional tasks like getting up from a chair and stepping down a step, and three questionnaires about the hip, the subject's general health, and how well the subject is able to function. also, subjects will be required to return to the clinic at several time points after surgery for follow-up visits. follow-up visits will include hip assessments and questionnaires, as well as follow-up hip x-rays. the follow-up visits will be 6 weeks, 3 months, 1 year, 2 years, 5 years, 7 years, and 10 years after hip replacement surgery. these follow-up visits are part of the study surgeon's normal routine for hip replacement patients, and are not extra visits as a part of this study.


Eligibility criteria:
inclusion criteria: * between ages of 18 and 85 * end stage hip joint degeneration * has elected to undergo primary total hip arthroplasty exclusion criteria: * undergoing revision arthroplasty * inflammatory or rheumatoid arthritis * patients with confounding medical conditions that are not expected to survive for the duration of follow-up (10 years) * body mass index greater than 40 kg/m2 * age \ than 85 * previous ipsilateral hip surgery including arthroscopic procedures
travatan z in ocular surface health in patients with open-angle glaucoma or ocular hypertension

Conditions: Open-angle Glaucoma; Ocular Hypertension

Summary: the purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * 18 years or older. * ocular surface disease index (osdi) score and corneal fluorescein staining score as specified in protocol. * diagnosis of open-angle glaucoma or ocular hypertension in at least one eye. * intraocular pressure (iop) controlled with latanoprost 0.005% (xalatan®) for at least one continuous month prior to visit 1. * willing and able to discontinue use of any topical ocular medication other than the study medication for the duration of the study, including artificial tears. * best corrected visual acuity of -0.6 logarithm of the minimum angle of resolution (logmar) or better in each eye. * other protocol-defined inclusion criteria may apply. exclusion criteria: * any medical condition (systemic or ophthalmic) that may preclude safe administration of the test article. * use of contact lenses within 30 days of visit 1. * use of contact lenses during the study. * participation in an investigational drug or device study within 30 days of entering this study. * other protocol-defined exclusion criteria may apply.
a feasibility study of chinese herbs to manage cancer-related symptoms in patients with advanced nsclc

Conditions: Lung Cancer

Summary: the current proposal is a feasibility and acceptability study to establish the necessary groundwork for more detailed investigations into the role of ch in reducing symptoms and improving quality of life in nsclc patients at the jewish general hospital (jgh). a standardized and easily administered form of ch will be used, incorporating a carefully selected combination of herbs designed to alleviate a range of common symptoms suffered by patients with advanced nsclc.

patients with advanced nsclc, in addition to their very poor chances of cure or extended survival, frequently suffer a range of different symptoms related to both their disease and its treatment. as a result there is a pressing need to develop more effective anti-cancer therapies and an imperative to enhance the effects of existing treatments and alleviate symptoms more effectively. increasing numbers of patients with cancer are using complementary medicine, including chinese herbs (ch), and evidence is accumulating from a growing number of laboratory studies and clinical trials, that ch may exert beneficial effects for cancer patients in many ways. the current proposal is a feasibility and acceptability study to establish the necessary groundwork for more detailed investigations into the role of ch in reducing symptoms and improving quality of life in nsclc patients at the jgh. a standardized and easily administered form of ch will be used, incorporating a carefully selected combination of herbs designed to alleviate a range of common symptoms suffered by patients with advanced nsclc. this is a prospective, longitudinal cohort study of a 6-week clinical intervention with chinese herbs in advanced (stage 4) nsclc patients all the active patients who have histologically or cytologically proven metastatic nsclc with eastern cooperative oncology group (ecog) performance status of 0 -2 will be eligible to participate in the study. quality of life will be assessed by fact-l and edmonton symptom assessment system (esas) questionnaires. patient will be instructed to complete a diary each day to confirm adherence to treatment and to indicate the reason(s) that any doses were missed or treatment was stopped.

Eligibility criteria:
inclusion criteria: * stages 4 * ecog performance ≤ 3 * life expectancy greater than ≥ 3 months exclusion criteria: * receiving tyrosine kinase inhibitors (tki), (tarceva, iressa) * brain metastases * patients or families who do not speak english or french * abnormal liver function: alanine aminotransaminase (alt) \> 40 u/l, aspartate aminotransaminase (ast) \> 55 u/l, alkaline phosphatase (alp) \> 145 u/l , bilirubin \> 1.7 umol/l. * taking regular anti-convulsants, coumadin or related anti-coagulant, lithium * taking regular immunosuppressive medications: azathioprine (imuran), basiliximab (simulect), cyclosporine (neoral, sandimmune), daclizumab (zenapax), muromonab-cd3 (okt3, orthoclone okt3), mycophenolate (cellcept), tacrolimus (fk506, prograf), sirolimus (rapamune)

Keywords: chinese herbs lung cancer quality of life
effects of uc-ii, glucosamine and curcumin supplementation on knee pain and inflammation.

Conditions: Inflammation; Knee Pain Chronic

Summary: this research evaluated the effects of ucii, glucosamine and curcumin supplementation on knee pain and inflammation.

arthritis is an inflammation of one or more joints, characterized by pain, stiffness (especially in the early morning or after exercise), swelling, deformation, and/or reduced mobility. there are many different forms of arthritis. osteoarthritis, also known as degenerative arthritis, is caused by abnormal damage to the cartilage at the ends of bones. in some patients, it is caused by injury or congenital abnormalities in the proteins that make up cartilage. generally, it seems that aging, an unbalanced diet, and an inappropriate lifestyle are the causes of this disease. once the cartilage tissue changes from smooth to rough or breaks into small pieces, the cartilage is gradually destroyed, and the normally smooth surface becomes irregular. osteoarthritis usually occurs in joints that bear weight, such as the spine, knees, hips, and back. it is usually preceded by pain and symptoms of stiffness (often stiffness first, then pain), but swelling is not always present. in a small number of cases, osteoarthritis can cause disability. as the condition progresses, the bones can become more fragmented, increasing the likelihood of fractures. when osteoarthritis is more severe, bones can overgrow into osteophytes, known as bone spurs. these bone spurs can be detected with x-rays, usually near degenerative cartilage in the neck or waist. however, these changes typically do not alter the appearance of the affected area. there are more than 28 types of peptides that make up collagen, with the more common types i, ii, and iii collagen accounting for about 90% of the total. type ii collagen forms joints. when collagen from pork bones and other sources is cooked at high temperatures, the collagen structure is destroyed, becoming denatured collagen. additional supplements can only be used as general collagen and, therefore, cannot reduce the damage and inflammation of joint cartilage. many studies have confirmed that the use of 'non-denatured type ii collagen' (uc-ii) can provide flexible maintenance for key parts. to achieve higher efficiency and longer-lasting effects, it is combined with glucosamine, chondroitin, and curcumin. in addition to providing resistance to compression in articular cartilage, it can also improve inflammation and significantly reduce pain in patients with primary osteoarthritis. therefore, this research evaluated the effects of ucii, glucosamine and curcumin supplementation on knee pain and inflammation.

Eligibility criteria:
inclusion criteria: * knee plain exclusion criteria: * severe diseases of the heart, liver, kidneys, endocrine system, and other organs * long-term use of medication * infection, hypertension, diabetes, cerebrovascular disease, heart disease, liver disease, kidney disease, gastrointestinal disease * allergy to this product

Keywords: non-denatured type ii collagen glucosamine curcumin knee pain
the effect of breakfasts varying in protein source on appetite and energy intake

Conditions: Obesity

Summary: over the last decades, changes in the diet and lifestyle have led to overall energy imbalance becoming commonplace and the emergence of an obesity epidemic with more than 1.6 billion adults being overweight. consumption of foods that can affect appetite by increasing satiety could regulate the total energy intake and thus body weight. there is data suggesting that the macronutrient composition of the foods and especially protein content may have a potent role on satiety. however, the type of protein appears to play a role in satiety possibly due to the different balance of the amino acid profile. the research project is dedicated to identify the source (animal or plant) and the optimized protein quantity needed to accelerate satiation, suppress appetite and extend satiety until hunger appears again. it is hypothesized that the consumption of animal derived protein-enriched meals will induce a reduction in hunger through the impact on gut hormones and peptides that are closely related to the short-term regulation of food intake.


Eligibility criteria:
inclusion criteria: * healthy males * age range 18-50 years * normal weight and overweight people as classified by bmi:20-29.9 kg/m2 (inclusive). * weight stable (within 3 kg) two months prior to study inclusion * understanding english well and feeling comfortable speaking it exclusion criteria: * dietary protein consumption \>25% energy from protein * had surgery in the previous 12 months * have suffered a myocardial infarction or stroke at any time * suffer from any blood-clotting disorder or prescription of any medication affecting blood clotting * suffer from any metabolic disorders (e.g. diabetes, metabolic syndrome or hypertension) * any requirement to take long-term medication, especially those active on the gastro-intestinal tract or for cardio-vascular disease * any dietary restrictions or recently/currently on a weight reducing diet * irregular eating patterns or not regularly consuming breakfast * food allergies (e.g. milk protein allergies) or intolerances (e.g. lactose) * use of medication which affects food intake or behaviour (e.g. anti-depressants) * use of medication likely to affect taste, smell or appetite * eating restraint based on the three factor eating questionnaire * use of any protein supplements * a history of alcohol or drug misuse (the average daily number of units of alcohol considered as acceptable is 2-3 units women; 3-4 units men * smoking * athletes in training (\>10 h exercise/week) * female that is breast-feeding, pregnant, or if of child-bearing potential and are not using effective contraceptive precautions * involvement in a study involving an experimental drug/medication within 3 months prior to entry of this study * blood pressure \> 160/90 mmhg * vegan or vegetarian * glucose \> 6 mmol/l * gamma glutamyl transpeptidase (liver enzymes) \> 1.9 μkat / l * alanine aminotransferase \> 1.1 μkat / l * cholesterol \> 6.5 mmol/l * triglycerides \> 2.0 mmol/l

Keywords: appetite amino acids protein source
enzastaurin in combination of capecitabine to treat breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to determine whether the combination of enzastaurin and capecitabine is more effective than the combination of placebo and capecitabine in treating participants with breast cancer who were previously treated with an anthracycline and a taxane.


Eligibility criteria:
inclusion criteria: * have been diagnosed with metastatic or recurrent breast cancer. * have been previously treated with both an anthracycline and a taxane. * have not received more than two prior chemotherapy treatment programs. * have stopped any antitumoral hormonal treatment before you enroll in this study. * have a negative pregnancy blood test if menstruating or capable of becoming pregnant. you must use an approved birth control method during the study and for 3 months after stopping study treatment. exclusion criteria: * cannot follow the study procedures (for example, you cannot swallow tablets). * are receiving another treatment for your cancer. * have received another experimental drug in the last 4 weeks. * have had serious heart disease within last 6 months. * are pregnant or breast-feeding.
preoperative self-assessment for cardio-pulmonary risk stratification

Conditions: Lung Diseases, Obstructive; Postoperative Complications; Cardiac Event

Summary: this prospective study intends to development and validation a patient self-assessment questionnaire. the aim of the self-assessment, by questionnaire, is to estimate the risk of postoperative pulmonary complications (ppc).

ppc are common adverse events operative patients. existing concepts of pulmonary risk evaluation are based on complex risk scores, preoperative apparatus examinations, laboratory parameters and medical findings. the significance of apparatus diagnostics for the preoperative pulmonary risk evaluation is highly controversial and guidelines recommend a reluctant use. a large prospective study (predict, unpublished to date, nct02566343) showed that lung function assessment in patients with copd symptoms undergoing major non-cardiac surgery did not improve the anamnestic risk assessment. in a large study it could be shown that a subjective self-assessment of physical performance by means of a structured questionnaire (dasi), in contrast to a subjective medical assessment, suitable for predicting perioperative cardiac events. our unpublished data show that a subjective self-assessment of "limited exercise capacity" in patients with copd is predictive of ppc is suitable. objectives: * development of a self-assessment questionnaire as part of a delphi trial * validation of the self-assessment questionnaire methodology: prospective observational, case control study of 5000 patients undergoing surgery in general anesthesia (estimated enrollment of 5500 patients with a dropout rate of approximately 10%).

Eligibility criteria:
inclusion criteria: * 18 years and older * operations in general anesthesia exclusion criteria: * \< 18 years * pregnancy * lack of cooperation

Keywords: self-assessment post operative pulmonary complication exercisetest
compliance of hcv genotype 1 infected patients receiving pegintron/rebetol and a patient assistance program (study p04671)

Conditions: Hepatitis C, Chronic; Hepatitis C

Summary: enrolled patients will be recruited to two parallel groups during therapy for hepatitis c. patients in the first one will receive a patient assistance program, and patients in the second group will not. all patients will receive pegintron and rebetol according to label.

non-probability sample, commercial product used according to eu label.

Eligibility criteria:
inclusion criteria: * according to pegintron/rebetol label. * only hcv genotype 1 infected patients will be enrolled in the study. exclusion criteria: * according to pegintron/rebetol label.
hydroxyapetite nanoparticles, tricalcium phosphate nanoparticles, and prf for treatment of gingival recession

Conditions: Periodontitis

Summary: the aim of the present study was to compare between nanocrystalline hydroxyapatite and tricalcium phosphate carried on prp membrane in treatment of miller's class 1 gingival recession in human.

gingival recession (gr) is apical movement of the gingival margin beyond the cement-enamel junction. the use of free gingival grafts, sliding pedicle grafts, subepithelial connective tissue grafts, envelope or tunnelling techniques, the use of acellular dermal, connective tissue allografts, guided tissue regeneration, platelet rich fibrin (prf), and coronally advanced flap (caf) are the surgical methods that have been developed to treat gingival recession. for treatments of intrabony defects, a synthetic nanocrystalline hydroxyapatite (ncha) bone graft has been introduced. osteoconductivity, bioresorbability, and close contact are benefits of ncha material. critical size defects showed quick healing when the ncha was utilised as a bone graft alternative. ncha binds to bone and increases osteoblast activity to promote bone regeneration. a promising bone replacement material, tricalcium phosphate (tcp) is known for its strong bioactivity and resorbable qualities. tricalcium phosphate (tcp) is one of the most popular and effective artificial bone substitutes. it is osteoinductive as well as osteoconductive. these characteristics enable full bone defects regeneration together with its cell-mediated resorption. in this study, we compared between nanocrystalline hydroxyapatite and tricalcium phosphate carried on prp membrane in treatment of miller's class 1 gingival recession in human.

Eligibility criteria:
inclusion criteria: * patients with good systemic health and no contraindication for periodontal surgery. * patients who are able to maintain good oral hygiene. * gingival thickness for the site selected should be ≥1mm. * the height of keratinized gingiva (hkg) for the site selected should be ≥1 mm (hkg is the distance between the most apical point of the gingival margin and the mucogingival junction). exclusion criteria: * active infectious diseases (hepatitis, tuberculosis, hiv, etc....). * medically compromised patients. * patients taking medications known to cause gingival enlargement. * pregnant patients and smokers. * previous mucogingival surgery at the defect. * restorations or caries in the area to be treated and non vital tooth. * teeth which are tilted or rotated.
rheumatoid arthritis comorbidity: bone health in men and african americans

Conditions: Rheumatoid Arthritis

Summary: the objective of the proposed study is to assess bone health and determinants of bone health among select subpopulations of rheumatoid arthritis patients.

the overall hypothesis of this study is that osteopenia and/or osteoporosis are common among african americans and men with rheumatoid arthritis and there are identifiable genetic and environmental factors contributing to the pathogenesis of bone loss in these groups. the specific aims of the study are to: 1. determine baseline hip and lumbar spine bone density (bmd) values and osteopenia/osteoporosis prevalence among african american men and women with early ra and among male veterans with established ra. 2. identify environmental factors and candidate alleles, which confer increased risk of reduced baseline bmd loss over time among african american men and women with early ra and among male veterans with established ra.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of rheumatoid arthritis per acr guidelines exclusion criteria: * patients with diagnosis \> 2yrs (clear study)

Keywords: rheumatoid arthritis african americans osteopenia osteoporosis bone mineral density